Emerging role of high mobility group box 1 in ANCA-associated vasculitis

Autoimmunity Reviews

Volumn 14, Issue 11, 2015, Pages 1057-1065

  Wang, Chen ^a   de Souza, Alexandre W S ^b,c   Westra, Johanna ^b   Bijl, Marc ^d   Chen, Min ^a   Zhao, Ming Hui ^a   Kallenberg, Cees G M ^b  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d MARTINI HOSPITAL   (Netherlands)

Author keywords

ANCA; HMGB1; Inflammation; Vasculitis

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN;

ANAPHYLACTOID PURPURA; ANCA ASSOCIATED VASCULITIS; AORTA ARCH SYNDROME; BLOOD CLOTTING; COMPLEMENT SYSTEM; DISEASE ACTIVITY; GIANT CELL ARTERITIS; HUMAN; INFLAMMATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; OXIDATION REDUCTION STATE; PROGNOSIS; REVIEW; SMALL VESSEL VASCULITIS; VASCULITIS; ANIMAL; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; COMPLICATION; IMMUNOLOGY;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; HMGB1 PROTEIN; HUMANS; INFLAMMATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; PURPURA, SCHOENLEIN-HENOCH;

EID: 84941261397     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.07.010     Document Type: Review

References (163)

1. Muller S., Ronfani L., Bianchi M.E. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 2004, 255:332-343.
2. Wen L., Huang J.K., Johnson B.H., Reeck G.R. A human placental cDNA clone that encodes nonhistone chromosomal protein HMG-1. Nucleic Acids Res 1989, 17:1197-1214.
3. Bianchi M.E., Falciola L., Ferrari S., Lilley D.M. The DNA binding site of HMG1 protein is composed of two similar segments (HMG boxes), both of which have counterparts in other eukaryotic regulatory proteins. EMBO J 1992, 11:1055-1063.
4. Einck L., Bustin M. The intracellular distribution and function of the high mobility group chromosomal proteins. Exp Cell Res 1985, 156:295-310.
5. Malarkey C.S., Churchill M.E. The high mobility group box: the ultimate utility player of a cell. Trends Biochem Sci 2012, 37:553-562.
6. Harris H.E., Andersson U., Pisetsky D.S. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012, 8:195-202.
7. Yanai H., Ban T., Taniguchi T. High-mobility group box family of proteins: ligand and sensor for innate immunity. Trends Immunol 2012, 33:633-640.
8. Andersson U., Tracey K.J. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011, 29:139-162.
9. Chen Y., Sun W., Gao R., Su Y., Umehara H., Dong L., et al. The role of high mobility group box chromosomal protein 1 in rheumatoid arthritis. Rheumatology (Oxford) 2013, 52:1739-1747.
10. Yang H., Antoine D.J., Andersson U., Tracey K.J. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol 2013, 93:865-873.
11. Abdulahad D.A., Westra J., Limburg P.C., Kallenberg C.G., Bijl M. HMGB1 in systemic lupus erythematosus: its role in cutaneous lesions development. Autoimmun Rev 2010, 9:661-665.
12. Andersson U., Erlandsson-Harris H. HMGB1 is a potent trigger of arthritis. J Intern Med 2004, 255:344-350.
13. de Souza A.W., Westra J., Limburg P.C., Bijl M., Kallenberg C.G. HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun Rev 2012, 11:909-917.
14. Ivanov S., Dragoi A.M., Wang X., Dallacosta C., Louten J., Musco G., et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007, 110:1970-1981.
15. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
16. Wang H., Vishnubhakat J.M., Bloom O., Zhang M., Ombrellino M., Sama A., et al. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999, 126:389-392.
17. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
18. Lu B., Wang C., Wang M., Li W., Chen F., Tracey K.J., et al. Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review. Expert Rev Clin Immunol 2014, 10:713-727.
19. Rendon-Mitchell B., Ochani M., Li J., Han J., Wang H., Yang H., et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 2003, 170:3890-3897.
20. Kawahara K., Biswas K.K., Unoshima M., Ito T., Kikuchi K., Morimoto Y., et al. C-reactive protein induces high-mobility group box-1 protein release through activation of p38MAPK in macrophage RAW264.7 cells. Cardiovasc Pathol 2008, 17:129-138.
21. Rittirsch D., Flierl M.A., Nadeau B.A., Day D.E., Huber-Lang M., Mackay C.R., et al. Functional roles for C5a receptors in sepsis. Nat Med 2008, 14:551-557.
22. Lu B., Antoine D.J., Kwan K., Lundback P., Wahamaa H., Schierbeck H., et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci U S A 2014, 111:3068-3073.
23. Lu B., Nakamura T., Inouye K., Li J., Tang Y., Lundback P., et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012, 488:670-674.
24. Ito I., Fukazawa J., Yoshida M. Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem 2007, 282:16336-16344.
25. Antoine D.J., Harris H.E., Andersson U., Tracey K.J., Bianchi M.E. A systematic nomenclature for the redox states of high mobility group box (HMGB) proteins. Mol Med 2014, 20:135-137.
26. Kazama H., Ricci J.E., Herndon J.M., Hoppe G., Green D.R., Ferguson T.A. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008, 29:21-32.
27. Schiraldi M., Raucci A., Munoz L.M., Livoti E., Celona B., Venereau E., et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 2012, 209:551-563.
28. Venereau E., Casalgrandi M., Schiraldi M., Antoine D.J., Cattaneo A., De Marchis F., et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 2012, 209:1519-1528.
29. Yang H., Lundback P., Ottosson L., Erlandsson-Harris H., Venereau E., Bianchi M.E., et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 2012, 18:250-259.
30. Maugeri N., Rovere-Querini P., Baldini M., Baldissera E., Sabbadini M.G., Bianchi M.E., et al. Oxidative stress elicits platelet/leukocyte inflammatory interactions via HMGB1: a candidate for microvessel injury in systemic sclerosis. Antioxid Redox Signal 2014, 20:1060-1074.
31. Tang D., Billiar T.R., Lotze M.T. A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol Med 2012, 18:1360-1362.
32. Tang D., Lotze M.T. Tumor immunity times out: TIM-3 and HMGB1. Nat Immunol 2012, 13:808-810.
33. Tian J., Avalos A.M., Mao S.Y., Chen B., Senthil K., Wu H., et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007, 8:487-496.
34. Venereau E., Schiraldi M., Uguccioni M., Bianchi M.E. HMGB1 and leukocyte migration during trauma and sterile inflammation. Mol Immunol 2013, 55:76-82.
35. Yanai H., Chiba S., Ban T., Nakaima Y., Onoe T., Honda K., et al. Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs). Proc Natl Acad Sci U S A 2011, 108:11542-11547.
36. Yang H., Tracey K.J. Targeting HMGB1 in inflammation. Biochim Biophys Acta 1799, 2010:149-156.
37. Agresti A., Lupo R., Bianchi M.E., Muller S. HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem Biophys Res Commun 2003, 302:421-426.
38. Jayaraman L., Moorthy N.C., Murthy K.G., Manley J.L., Bustin M., Prives C. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev 1998, 12:462-472.
39. Verrijdt G., Haelens A., Schoenmakers E., Rombauts W., Claessens F. Comparative analysis of the influence of the high-mobility group box 1 protein on DNA binding and transcriptional activation by the androgen, glucocorticoid, progesterone and mineralocorticoid receptors. Biochem J 2002, 361:97-103.
40. Andersson U., Wang H., Palmblad K., Aveberger A.C., Bloom O., Erlandsson-Harris H., et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000, 192:565-570.
41. Yang H., Hreggvidsdottir H.S., Palmblad K., Wang H., Ochani M., Li J., et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A 2010, 107:11942-11947.
42. Rouhiainen A., Kuja-Panula J., Wilkman E., Pakkanen J., Stenfors J., Tuominen R.K., et al. Regulation of monocyte migration by amphoterin (HMGB1). Blood 2004, 104:1174-1182.
43. Rouhiainen A., Tumova S., Valmu L., Kalkkinen N., Rauvala H. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol 2007, 81:49-58.
44. DeMarco R.A., Fink M.P., Lotze M.T. Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol 2005, 42:433-444.
45. Wang X., Sun R., Wei H., Tian Z. High-mobility group box 1 (HMGB1)-Toll-like receptor (TLR)4-interleukin (IL)-23-IL-17A axis in drug-induced damage-associated lethal hepatitis: interaction of gammadelta T cells with macrophages. Hepatology 2013, 57:373-384.
46. Park J.S., Arcaroli J., Yum H.K., Yang H., Wang H., Yang K.Y., et al. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 2003, 284:C870-C879.
47. Berthelot F., Fattoum L., Casulli S., Gozlan J., Marechal V., Elbim C. The effect of HMGB1, a damage-associated molecular pattern molecule, on polymorphonuclear neutrophil migration depends on its concentration. J Innate Immun 2012, 4:41-58.
48. Huebener P., Pradere J.P., Hernandez C., Gwak G.Y., Caviglia J.M., Mu X., et al. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J Clin Invest 2015, 125:539-550.
49. Orlova V.V., Choi E.Y., Xie C., Chavakis E., Bierhaus A., Ihanus E., et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 2007, 26:1129-1139.
50. Wang C., Wang H., Chang D.Y., Hao J., Zhao M.H., Chen M. High mobility group box 1 contributes to anti-neutrophil cytoplasmic antibody-induced neutrophils activation through receptor for advanced glycation end products (RAGE) and Toll-like receptor 4. Arthritis Res Ther 2015, 17:64.
51. Fan J., Li Y., Levy R.M., Fan J.J., Hackam D.J., Vodovotz Y., et al. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J Immunol 2007, 178:6573-6580.
52. Tadie J.M., Bae H.B., Banerjee S., Zmijewski J.W., Abraham E. Differential activation of RAGE by HMGB1 modulates neutrophil-associated NADPH oxidase activity and bacterial killing. Am J Physiol Cell Physiol 2012, 302:C249-C256.
53. Huang H.T.S., Al-Khafaji A.B., Tai S., Loughran P., Chen L., Wang S. DAMPs-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury. Hepatology 2015, Epub 2015 Apr 8.
54. Tadie J.M., Bae H.B., Jiang S., Park D.W., Bell C.P., Yang H., et al. HMGB1 promotes neutrophil extracellular trap formation through interactions with Toll-like receptor 4. Am J Physiol Lung Cell Mol Physiol 2013, 304:L342-L349.
55. Campana L., Bosurgi L., Bianchi M.E., Manfredi A.A., Rovere-Querini P. Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J Leukoc Biol 2009, 86:609-615.
56. Dumitriu I.E., Baruah P., Bianchi M.E., Manfredi A.A., Rovere-Querini P. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur J Immunol 2005, 35:2184-2190.
57. Dumitriu I.E., Bianchi M.E., Bacci M., Manfredi A.A., Rovere-Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 2007, 81:84-91.
58. Messmer D., Yang H., Telusma G., Knoll F., Li J., Messmer B., et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004, 173:307-313.
59. Semino C., Angelini G., Poggi A., Rubartelli A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 2005, 106:609-616.
60. Semino C., Ceccarelli J., Lotti L.V., Torrisi M.R., Angelini G., Rubartelli A. The maturation potential of NK cell clones toward autologous dendritic cells correlates with HMGB1 secretion. J Leukoc Biol 2007, 81:92-99.
61. Dumitriu I.E., Baruah P., Valentinis B., Voll R.E., Herrmann M., Nawroth P.P., et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005, 174:7506-7515.
62. Jube S., Rivera Z.S., Bianchi M.E., Powers A., Wang E., Pagano I., et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 2012, 72:3290-3301.
63. Sundberg E., Fasth A.E., Palmblad K., Harris H.E., Andersson U. High mobility group box chromosomal protein 1 acts as a proliferation signal for activated T lymphocytes. Immunobiology 2009, 214:303-309.
64. Zhu X.M., Yao Y.M., Liang H.P., Xu C.T., Dong N., Yu Y., et al. High mobility group box-1 protein regulate immunosuppression of regulatory T cells through toll-like receptor 4. Cytokine 2011, 54:296-304.
65. Duan L., Wang C.Y., Chen J., Gong Q., Zhu P., Zheng F., et al. High-mobility group box 1 promotes early acute allograft rejection by enhancing IL-6-dependent Th17 alloreactive response. Lab Invest 2011, 91:43-53.
66. He Z., Shotorbani S.S., Jiao Z., Su Z., Tong J., Liu Y., et al. HMGB1 promotes the differentiation of Th17 via up-regulating TLR2 and IL-23 of CD14+ monocytes from patients with rheumatoid arthritis. Scand J Immunol 2012, 76:483-490.
67. Shi Y., Sandoghchian Shotorbani S., Su Z., Liu Y., Tong J., Zheng D., et al. Enhanced HMGB1 expression may contribute to Th17 cells activation in rheumatoid arthritis. Clin Dev Immunol 2012, 2012:295081.
68. Su Z., Sun C., Zhou C., Liu Y., Zhu H., Sandoghchian S., et al. HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17-cell expansion. Eur J Immunol 2011, 41:3586-3595.
69. Avalos A.M., Kiefer K., Tian J., Christensen S., Shlomchik M., Coyle A.J., et al. RAGE-independent autoreactive B cell activation in response to chromatin and HMGB1/DNA immune complexes. Autoimmunity 2010, 43:103-110.
70. Fiuza C., Bustin M., Talwar S., Tropea M., Gerstenberger E., Shelhamer J.H., et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003, 101:2652-2660.
71. Treutiger C.J., Mullins G.E., Johansson A.S., Rouhiainen A., Rauvala H.M., Erlandsson-Harris H., et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003, 254:375-385.
72. Jiang R., Cai J., Zhu Z., Chen D., Wang J., Wang Q., et al. Hypoxic trophoblast HMGB1 induces endothelial cell hyperpermeability via the TRL-4/caveolin-1 pathway. J Immunol 2014, 193:5000-5012.
73. Lee W., Ku S.K., Kim J.A., Lee T., Bae J.S. Inhibitory effects of epi-sesamin on HMGB1-induced vascular barrier disruptive responses in vitro and in vivo. Toxicol Appl Pharmacol 2013, 267:201-208.
74. Zou M., Dong H., Meng X., Cai C., Li C., Cai S., et al. Store-operated Ca2+ entry plays a role in HMGB1-induced vascular endothelial cell hyperpermeability. PLoS One 2015, 10:e0123432.
75. Lee W., Kwon O.K., Han M.S., Lee Y.M., Kim S.W., Kim K.M., et al. Role of moesin in HMGB1-stimulated severe inflammatory responses. Thromb Haemost 2015, 114.
76. Wolfson R.K., Chiang E.T., Garcia J.G. HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption. Microvasc Res 2011, 81:189-197.
77. Li J., Wang F.P., She W.M., Yang C.Q., Li L., Tu C.T., et al. Enhanced high-mobility group box 1 (HMGB1) modulates regulatory T cells (Treg)/T helper 17 (Th17) balance via toll-like receptor (TLR)-4-interleukin (IL)-6 pathway in patients with chronic hepatitis B. J Viral Hepat 2014, 21:129-140.
78. Mullins G.E., Sunden-Cullberg J., Johansson A.S., Rouhiainen A., Erlandsson-Harris H., Yang H., et al. Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scand J Immunol 2004, 60:566-573.
79. Haubitz M., Woywodt A. Circulating endothelial cells and vasculitis. Intern Med 2004, 43:660-667.
80. Cai C., Gill R., Eum H.A., Cao Z., Loughran P.A., Darwiche S., et al. Complement factor 3 deficiency attenuates hemorrhagic shock-related hepatic injury and systemic inflammatory response syndrome. Am J Physiol Regul Integr Comp Physiol 2010, 299:R1175-R1182.
81. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680.
82. Kaisho T., Akira S. Toll-like receptors and their signaling mechanism in innate immunity. Acta Odontol Scand 2001, 59:124-130.
83. Markiewski M.M., Lambris J.D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007, 171:715-727.
84. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001, 1:135-145.
85. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826.
86. Fang C., Zhang X., Miwa T., Song W.C. Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production. Blood 2009, 114:1005-1015.
87. Fraser D.A., Arora M., Bohlson S.S., Lozano E., Tenner A.J. Generation of inhibitory NFkappaB complexes and phosphorylated cAMP response element-binding protein correlates with the anti-inflammatory activity of complement protein C1q in human monocytes. J Biol Chem 2007, 282:7360-7367.
88. Hajishengallis G., Wang M., Liang S. Induction of distinct TLR2-mediated proinflammatory and proadhesive signaling pathways in response to Porphyromonas gingivalis fimbriae. J Immunol 2009, 182:6690-6696.
89. la Sala A., Gadina M., Kelsall B.L. G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK. J Immunol 2005, 175:2994-2999.
90. Lappegard K.T., Christiansen D., Pharo A., Thorgersen E.B., Hellerud B.C., Lindstad J., et al. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc Natl Acad Sci U S A 2009, 106:15861-15866.
91. Mangsbo S.M., Sanchez J., Anger K., Lambris J.D., Ekdahl K.N., Loskog A.S., et al. Complement activation by CpG in a human whole blood loop system: mechanisms and immunomodulatory effects. J Immunol 2009, 183:6724-6732.
92. Oliva C., Turnbough C.L., Kearney J.F. CD14-Mac-1 interactions in Bacillus anthracis spore internalization by macrophages. Proc Natl Acad Sci U S A 2009, 106:13957-13962.
93. Zhang X., Kimura Y., Fang C., Zhou L., Sfyroera G., Lambris J.D., et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 2007, 110:228-236.
94. Ito T., Kawahara K., Nakamura T., Yamada S., Nakamura T., Abeyama K., et al. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost 2007, 5:109-116.
95. Lv B., Wang H., Tang Y., Fan Z., Xiao X., Chen F. High-mobility group box 1 protein induces tissue factor expression in vascular endothelial cells via activation of NF-kappaB and Egr-1. Thromb Haemost 2009, 102:352-359.
96. van Zoelen M.A., Yang H., Florquin S., Meijers J.C., Akira S., Arnold B., et al. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 2009, 31:280-284.
97. Maugeri N., Campana L., Gavina M., Covino C., De Metrio M., Panciroli C., et al. Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. J Thromb Haemost 2014, 12:2074-2088.
98. Lee W., Ku S.K., Bae J.S. Factor Xa inhibits HMGB1-induced septic responses in human umbilical vein endothelial cells and in mice. Thromb Haemost 2014, 112:757-769.
99. Abeyama K., Stern D.M., Ito Y., Kawahara K., Yoshimoto Y., Tanaka M., et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005, 115:1267-1274.
100. Esmon C. Do-all receptor takes on coagulation, inflammation. Nat Med 2005, 11:475-477.
101. Sato F., Maruyama S., Hayashi H., Sakamoto I., Yamada S., Uchimura T., et al. High mobility group box chromosomal protein 1 in patients with renal diseases. Nephron Clin Pract 2008, 108:c194-c201.
102. Ito T., Maruyama I. Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost 2011, 9(Suppl. 1):168-173.
103. Ito T., Kawahara K., Okamoto K., Yamada S., Yasuda M., Imaizumi H., et al. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 2008, 28:1825-1830.
104. Bruchfeld A., Wendt M., Bratt J., Qureshi A.R., Chavan S., Tracey K.J., et al. High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med 2011, 17:29-35.
105. Chen T., Guo Z.P., Wang W.J., Qin S., Cao N., Li M.M. Increased serum HMGB1 levels in patients with Henoch-Schonlein purpura. Exp Dermatol 2014, 23:419-423.
106. de Souza A., Westra J., Bijzet J., Limburg P.C., Stegeman C.A., Bijl M., et al. Is serum HMGB1 a biomarker in ANCA-associated vasculitis?. Arthritis Res Ther 2013, 15:R104.
107. de Souza A.W., Abdulahad W.H., Sosicka P., Bijzet J., Limburg P.C., Stegeman C.A., et al. Are urinary levels of high mobility group box 1 markers of active nephritis in anti-neutrophil cytoplasmic antibody-associated vasculitis?. Clin Exp Immunol 2014, 178:270-278.
108. Eguchi T., Nomura Y., Hashiguchi T., Masuda K., Arata M., Hazeki D., et al. An elevated value of high mobility group box 1 is a potential marker for poor response to high-dose of intravenous immunoglobulin treatment in patients with Kawasaki syndrome. Pediatr Infect Dis J 2009, 28:339-341.
109. Henes F.O., Chen Y., Bley T.A., Fabel M., Both M., Herrmann K., et al. Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis 2011, 70:1926-1929.
110. Hoshina T., Kusuhara K., Ikeda K., Mizuno Y., Saito M., Hara T. High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease. Scand J Rheumatol 2008, 37:445-449.
111. Souza A.W., de Leeuw K., van Timmeren M.M., Limburg P.C., Stegeman C.A., Bijl M., et al. Impact of serum high mobility group box 1 and soluble receptor for advanced glycation end-products on subclinical atherosclerosis in patients with granulomatosis with polyangiitis. PLoS One 2014, 9:e96067.
112. Wang C., Gou S.J., Chang D.Y., Yu F., Zhao M.H., Chen M. Association of circulating level of high mobility group box 1 with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Care Res 2013, 65:1828-1834.
113. Wibisono D., Csernok E., Lamprecht P., Holle J.U., Gross W.L., Moosig F. Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis. Ann Rheum Dis 2010, 69:1888-1889.
114. Ma T.T., Wang H., Wang C., Chang D.Y., Zhao M.H., Chen M. Urinary levels of high mobility group box-1 are associated with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis. PLoS One 2015, 10:e0123586.
115. de Souza A.W., van der Geest K.S., Brouwer E., Pinheiro F.A., Oliveira A.C., Sato E.I., et al. High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins. Arthritis Res Ther 2015, 17:158.
116. Jennette J.C., Falk R.J., Bacon P.A., Basu N., Cid M.C., Ferrario F., et al. 2012 Revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013, 65:1-11.
117. Newburger J.W., Takahashi M., Gerber M.A., Gewitz M.H., Tani L.Y., Burns J.C., et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004, 110:2747-2771.
118. Ozen S., Pistorio A., Iusan S.M., Bakkaloglu A., Herlin T., Brik R., et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010, 69:798-806.
119. Falk R.J., Jennette J.C. ANCA small-vessel vasculitis. J Am Soc Nephrol 1997, 8:314-322.
120. Segelmark M., Wieslander J. IgG subclasses of antineutrophil cytoplasm autoantibodies (ANCA). Nephrol Dial Transplant 1993, 8:696-702.
121. Chen M., Yu F., Zhang Y., Zou W.Z., Zhao M.H., Wang H.Y. Characteristics of Chinese patients with Wegener's granulomatosis with anti-myeloperoxidase autoantibodies. Kidney Int 2005, 68:2225-2229.
122. Charles L.A., Caldas M.L., Falk R.J., Terrell R.S., Jennette J.C. Antibodies against granule proteins activate neutrophils in vitro. J Leukoc Biol 1991, 50:539-546.
123. Falk R.J., Terrell R.S., Charles L.A., Jennette J.C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990, 87:4115-4119.
124. Hess C., Sadallah S., Schifferli J.A. Induction of neutrophil responsiveness to myeloperoxidase antibodies by their exposure to supernatant of degranulated autologous neutrophils. Blood 2000, 96:2822-2827.
125. Keogan M.T., Esnault V.L., Green A.J., Lockwood C.M., Brown D.L. Activation of normal neutrophils by anti-neutrophil cytoplasm antibodies. Clin Exp Immunol 1992, 90:228-234.
126. Mulder A.H., Heeringa P., Brouwer E., Limburg P.C., Kallenberg C.G. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol 1994, 98:270-278.
127. Mulder A.H., Stegeman C.A., Kallenberg C.G. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: a predominant role for the IgG3 subclass of ANCA. Clin Exp Immunol 1995, 101:227-232.
128. Xiao H., Heeringa P., Hu P., Liu Z., Zhao M., Aratani Y., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002, 110:955-963.
129. Xiao H., Heeringa P., Liu Z., Huugen D., Hu P., Maeda N., et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 2005, 167:39-45.
130. Huugen D., van Esch A., Xiao H., Peutz-Kootstra C.J., Buurman W.A., Tervaert J.W., et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 2007, 71:646-654.
131. Xiao H., Schreiber A., Heeringa P., Falk R.J., Jennette J.C. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007, 170:52-64.
132. Gou S.J., Yuan J., Chen M., Yu F., Zhao M.H. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 2013, 83:129-137.
133. Gou S.J., Yuan J., Wang C., Zhao M.H., Chen M. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clin J Am Soc Nephrol 2013, 8:1884-1891.
134. Xing G.Q., Chen M., Liu G., Heeringa P., Zhang J.J., Zheng X., et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2009, 29:282-291.
135. Guo R.F., Ward P.A. Role of C5a in inflammatory responses. Annu Rev Immunol 2005, 23:821-852.
136. Schreiber A., Xiao H., Jennette J.C., Schneider W., Luft F.C., Kettritz R. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009, 20:289-298.
137. Cantrell J.W., Stroud R.M., Pruitt K.M. Insulin and IgG complexes. An immunologic bypass for complement activation. Diabetes 1972, 21:872-880.
138. Johnston R.B., Stroud R.M. Complement and host defense against infection. J Pediatr 1977, 90:169-179.
139. Morrison D.C., Kline L.F. Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS). J Immunol 1977, 118:362-368.
140. Wagner T., Abraham G., Baum J. The roles of IgG, IgM rheumatoid factor, and their complexes in the induction of polymorphonuclear leukocyte chemotactic factor from complement. J Clin Invest 1974, 53:1503-1511.
141. Wang H., Wang C., Zhao M.H., Chen M. Neutrophil extracellular traps can activate alternative complement pathways. Clin Exp Immunol 2015, Epub 2015 May 11.
142. Chen S.F., Wang F.M., Li Z.Y., Yu F., Zhao M.H., Chen M. Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis. Arthritis Res Ther 2015, 17:129.
143. Wang C., Wang H., Hao J., Chang D.Y., Zhao M.H., Chen M. Involvement of high mobility group box 1 in the activation of C5a-primed neutrophils induced by ANCA. Clin Immunol 2015, 159:47-57.
144. Hilhorst M., Winckers K., Wilde B., van Oerle R., ten Cate H., Tervaert J.W. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J Rheumatol 2013, 40:2042-2046.
145. Kambas K., Chrysanthopoulou A., Vassilopoulos D., Apostolidou E., Skendros P., Girod A., et al. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. Ann Rheum Dis 2014, 73:1854-1863.
146. Huang Y.M., Wang H., Wang C., Chen M., Zhao M.H. C5a inducing tissue factor expressing microparticles and neutrophil extracellular traps promote hypercoagulability in ANCA-associated vasculitis. Arthritis Rheum 2015, Epub 2015 Jun 19.
147. Abdulahad W.H., Stegeman C.A., Limburg P.C., Kallenberg C.G. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum 2008, 58:2196-2205.
148. Abdulahad W.H., van der Geld Y.M., Stegeman C.A., Kallenberg C.G. Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int 2006, 70:938-947.
149. Marinaki S., Neumann I., Kalsch A.I., Grimminger P., Breedijk A., Birck R., et al. Abnormalities of CD4 T cell subpopulations in ANCA-associated vasculitis. Clin Exp Immunol 2005, 140:181-191.
150. Popa E.R., Stegeman C.A., Bos N.A., Kallenberg C.G., Tervaert J.W. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999, 103:885-894.
151. Saito H., Tsurikisawa N., Tsuburai T., Oshikata C., Akiyama K. Cytokine production profile of CD4+ T cells from patients with active Churg-Strauss syndrome tends toward Th17. Int Arch Allergy Immunol 2009, 149(Suppl. 1):61-65.
152. Wilde B., Dolff S., Cai X., Specker C., Becker J., Totsch M., et al. CD4+CD25+ T-cell populations expressing CD134 and GITR are associated with disease activity in patients with Wegener's granulomatosis. Nephrol Dial Transplant 2009, 24:161-171.
153. Abdulahad W.H., Stegeman C.A., van der Geld Y.M., Doornbos-van der Meer B., Limburg P.C., Kallenberg C.G. Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum 2007, 56:2080-2091.
154. Free M.E., Bunch D.O., McGregor J.A., Jones B.E., Berg E.A., Hogan S.L., et al. Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum 2013, 65:1922-1933.
155. Rimbert M., Hamidou M., Braudeau C., Puechal X., Teixeira L., Caillon H., et al. Decreased numbers of blood dendritic cells and defective function of regulatory T cells in antineutrophil cytoplasmic antibody-associated vasculitis. PLoS One 2011, 6:e18734.
156. Kessenbrock K., Krumbholz M., Schonermarck U., Back W., Gross W.L., Werb Z., et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009, 15:623-625.
157. Nakazawa D., Shida H., Tomaru U., Yoshida M., Nishio S., Atsumi T., et al. Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis. J Am Soc Nephrol 2014, 25:990-997.
158. Gero D., Szoleczky P., Modis K., Pribis J.P., Al-Abed Y., Yang H., et al. Identification of pharmacological modulators of HMGB1-induced inflammatory response by cell-based screening. PLoS One 2013, 8:e65994.
159. Andrassy M., Volz H.C., Igwe J.C., Funke B., Eichberger S.N., Kaya Z., et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008, 117:3216-3226.
160. Kokkola R., Li J., Sundberg E., Aveberger A.C., Palmblad K., Yang H., et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003, 48:2052-2058.
161. Lamkanfi M., Sarkar A., Vande Walle L., Vitari A.C., Amer A.O., Wewers M.D., et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol 2010, 185:4385-4392.
162. Tsung A., Sahai R., Tanaka H., Nakao A., Fink M.P., Lotze M.T., et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005, 201:1135-1143.
163. Raman K.G., Sappington P.L., Yang R., Levy R.M., Prince J.M., Liu S., et al. The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol 2006, 291:G556-G565.